2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159118
    PC-Qz1 98%
    PC-Qz1 is a mitochondrial NADH-ubiquinone oxidoreductase (complex I) inhibitor with an IC50 of 470 nM. PC-Qz1 has antibacterial activity.
    PC-Qz1
  • HY-159477
    SARS-CoV-2-IN-92 2123489-12-1 98%
    SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II.
    SARS-CoV-2-IN-92
  • HY-159603
    S-WJM992 98%
    S-WJM992 (compound 10ahb) is an antiparasitic agent that inhibits ATPase activity under high [Na+] conditions. S-WJM992 also has significant inhibitory effects on parasites that have developed PfATP4 inhibitor-resistance. S-WJM992 is a potential transmission blocker that effectively inhibits gamete development and prevents parasite transmission to mosquitoes via blood feeding.
    S-WJM992
  • HY-159628
    Glu-AMS 859213-87-9
    Glu-AMS is a competitive inhibitor of Escherichia coli glutamyl-tRNA synthetase (GluRS), with the Ki of 2.8 nM.
    Glu-AMS
  • HY-159640
    NVP-FVP954 98%
    NVP-FVP954 is a fast-acting antimalarial agent with potential for severe malaria. FVP954 has a high barrier to resistance, long half-life, and high solubility, making it suitable for intravenous administration.
    NVP-FVP954
  • HY-159666
    Nystatin A1 34786-70-4 98%
    Nystatin A1 is a polyene macrolide antifungal antibiotic that can be isolated from Streptomyces noursei. Nystatin A1 binds to ergosterol on the fungal cell membrane, increasing the permeability of the cell membrane and causing leakage of cell contents, thereby inhibiting the growth and reproduction of fungi.
    Nystatin A1
  • HY-159687
    Nafithromycin 1691240-78-4 98%
    Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter.
    Nafithromycin
  • HY-15971R
    AMD 3465 hexahydrobromide (Standard) 185991-07-5
    AMD 3465 (hexahydrobromide) (Standard) is the analytical standard of AMD 3465 (hexahydrobromide). This product is intended for research and analytical applications. AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
    AMD 3465 hexahydrobromide (Standard)
  • HY-159737
    Rociclovir 108436-80-2 98%
    Rociclovir (HOE 602) is an acyclic nucleoside derivative. Rociclovir protects mice against HSV and MCMV infections, but lacks antiviral activity in cell cultures.
    Rociclovir
  • HY-159823
    Suricapavir 2417270-21-2 98%
    Suricapavir is a potent viral replication inhibitor. Suricapavir shows antiviral activity.
    Suricapavir
  • HY-159879
    AAK1-IN-6 3061058-16-7 98%
    AAK1-IN-6 (Compound 23) is an inhibitor of AP-2-associated protein kinase 1 (AAK1, IC50 = 12 nM) with antiviral activity against the dengue virus (DNEV2, EC50 = 0.24 μM) and Venezuelan equine encephalitis virus (VEEV, EC50 = 0.30 μM). AAK1-IN-6 can be utilized in antiviral research.
    AAK1-IN-6
  • HY-159883
    DDHF20 98%
    DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.
    DDHF20
  • HY-159900
    Antimalarial agent 46 2715225-19-5 98%
    Antimalarial agent 46 (Compound 42a) is an antimalarial agent with antimalarial activity. Antimalarial agent 46 shows inhibitory activity against P. falciparum lines.
    Antimalarial agent 46
  • HY-159915
    Se2h 98%
    Se2h is a cruzain inhibitor that exhibits strong activity against the intracellular amastigotes of Trypanosoma cruzi (EC50 < 1 μM, SI > 10), with an inhibitory activity against cruzain of IC50 < 100 nM (SI > 5.55). Compared to Benznidazole (HY-B1548) and the cruzain inhibitor K777 (HY-119293), Se2h shows superior selectivity and inhibition, while its selenazole structure reduces selenium-related toxicity. Se2h exhibits antiparasitic activity and holds promise for research in Chagas disease.
    Se2h
  • HY-159929
    Antibiotic adjuvant 2 98%
    Antibiotic adjuvant 2 (compound 5q) is an antibiotic adjuvant with potent colistin-potentiating activity and low mammalian toxicity. Antibiotic adjuvant 2 has minimum re-sensitizing concentration of 0.125 μg/mL agnist of Escherichia coli AR-0493.
    Antibiotic adjuvant 2
  • HY-159930
    Antibiotic adjuvant 3 2972593-21-6 98%
    Antibiotic adjuvant 3 (compound 8g) is an antibiotic adjuvant with potent colistin-potentiating activity and low mammalian toxicity. Antibiotic adjuvant 3 has minimum re-sensitizing concentration of 0.25 μg/mL agnist of Escherichia coli AR-0493.
    Antibiotic adjuvant 3
  • HY-159932
    SARS-CoV-2 Mpro-IN-30 3107600-77-8 98%
    SARS-CoV-2 Mpro-IN-30 (compound L2) is a SARS-CoV-2 Mpro with the IC50 of 9.1 nM.
    SARS-CoV-2 Mpro-IN-30
  • HY-159933
    SARS-CoV-2-IN-105 98%
    SARS-CoV-2-IN-105 (Compound 4a) is a SARS-CoV-2 inhibitor with the EC50 of 0.69 μM.
    SARS-CoV-2-IN-105
  • HY-159960
    Carbonic anhydrase inhibitor 28 98%
    Carbonic anhydrase inhibitor 28 (Compound 11) is a Pseudomonas aeruginosa carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 28 exhibits antimicrobial activity, with a MIC of 0.5 μg/mL and a MBC of 1 μg/mL against P. aeruginosa. Carbonic anhydrase inhibitor 28 can be used in anti-infection research.
    Carbonic anhydrase inhibitor 28
  • HY-159961
    SARS-CoV-2 Mpro-IN-34 98%
    SARS-CoV-2 Mpro-IN-34 (Compound 26) is an inhibitor for SARS-CoV-2 Mpro with an IC50 of 6 nM. SARS-CoV-2 Mpro-IN-34 exhibits inhibitory efficacy against OC43 Mpro with an IC50 of 33 nM. SARS-CoV-2 Mpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected Vero E6 cell with an EC50 of 0.103 μM.
    SARS-CoV-2 Mpro-IN-34
Cat. No. Product Name / Synonyms Application Reactivity